Nothing Special   »   [go: up one dir, main page]

ES2150482T3 - Pirazolopirimidinas como antagonistas del factor liberador de corticotropina. - Google Patents

Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.

Info

Publication number
ES2150482T3
ES2150482T3 ES94903283T ES94903283T ES2150482T3 ES 2150482 T3 ES2150482 T3 ES 2150482T3 ES 94903283 T ES94903283 T ES 94903283T ES 94903283 T ES94903283 T ES 94903283T ES 2150482 T3 ES2150482 T3 ES 2150482T3
Authority
ES
Spain
Prior art keywords
pirazolopirimidines
antagonists
releasing factor
corticotropin releasing
scr1r2r11
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903283T
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2150482T3 publication Critical patent/ES2150482T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ANTAGONISTAS (CRF) DE FACTOR DE LIBERACION DE CORTICOTROPINA TIENE LA FORMULA (I) DONDE A, R3, R4, R5 Y R6 SE DEFINEN AQUI. SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INDUCIDAS O FACILITADAS POR CRF, TALES COMO TRASTORNOS INFAMATORIOS, Y TRASTORNOS RELACIONADOS CON LA DEPRESION Y LA ANSIEDAD.
ES94903283T 1992-12-17 1993-11-26 Pirazolopirimidinas como antagonistas del factor liberador de corticotropina. Expired - Lifetime ES2150482T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99222992A 1992-12-17 1992-12-17
PCT/US1993/011333 WO1994013677A1 (en) 1992-12-17 1993-11-26 Pyrazolopyrimidines as crf antagonists

Publications (1)

Publication Number Publication Date
ES2150482T3 true ES2150482T3 (es) 2000-12-01

Family

ID=25538069

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903283T Expired - Lifetime ES2150482T3 (es) 1992-12-17 1993-11-26 Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.

Country Status (27)

Country Link
US (1) US6218397B1 (es)
EP (1) EP0674642B1 (es)
JP (1) JP2862375B2 (es)
KR (2) KR0167395B1 (es)
CN (1) CN1034175C (es)
AT (1) ATE195738T1 (es)
AU (1) AU680226B2 (es)
BR (1) BR9307648A (es)
CA (1) CA2150709C (es)
CZ (1) CZ287319B6 (es)
DE (1) DE69329296T2 (es)
DK (1) DK0674642T3 (es)
EG (1) EG20273A (es)
ES (1) ES2150482T3 (es)
FI (1) FI105920B (es)
GR (1) GR3034507T3 (es)
HU (1) HU221507B (es)
IL (1) IL107944A (es)
MY (1) MY115300A (es)
NO (1) NO305437B1 (es)
NZ (1) NZ259114A (es)
PL (1) PL177028B1 (es)
PT (1) PT674642E (es)
RU (1) RU2124016C1 (es)
TW (2) TW444018B (es)
WO (1) WO1994013677A1 (es)
ZA (1) ZA939405B (es)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU1884595A (en) * 1994-04-29 1995-11-29 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
WO1995034563A1 (en) 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5747495A (en) * 1995-08-22 1998-05-05 Hiroshi Maeda Method for treating hypertension using pyrazolopyrimidine derivatives
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
CA2233307A1 (en) * 1996-02-07 1997-08-14 Terence J. Moran Thiophenopyrimidines
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
DK0880523T3 (da) * 1996-02-07 2007-03-26 Neurocrine Biosciences Inc Pyrazolopyrimidiner som CRF-receptorantagonister
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
WO1997035846A1 (en) * 1996-03-26 1997-10-02 Dupont Pharmaceuticals Company Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
KR100298523B1 (ko) * 1996-06-06 2001-09-06 오쓰카 요시미쓰 아미드유도체
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
IL128188A0 (en) * 1996-08-06 1999-11-30 Pfizer ,7-bicyclic derivatives substituted pyrido-or pyrimido-containing 6,6-or 6
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
AU9041198A (en) * 1997-09-02 1999-03-22 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
EP1068205A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
ATE225349T1 (de) * 1998-11-12 2002-10-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
JP2002529469A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6518266B1 (en) 1999-07-22 2003-02-11 3-Dimensional Pharmaceuticals 1- Aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
OA12050A (en) * 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
US6545033B1 (en) 1999-10-06 2003-04-08 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
KR100875595B1 (ko) 2001-03-13 2008-12-23 브리스톨-마이어스 스퀴브 파마 컴파니 코르티코트로핀 방출인자 수용체 리간드로서4-(2-부틸아미노)-2,7-디메틸-8-(2-메틸-6-메톡시피리드-3-일) 피라졸로-[1,5-에이]-1,3,5-트리아진, 그의 거울상이성질체 및 약학적으로 허용가능한 염
ES2366082T3 (es) 2001-04-27 2011-10-17 EISAI R&D MANAGEMENT CO., LTD. Pirazolo 1,5-a piridinas y medicinas que las contienen.
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US6815444B2 (en) * 2002-05-24 2004-11-09 National Health Research Institutes Anti-enterovirus compounds
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
KR100984085B1 (ko) 2002-10-22 2010-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 7-페닐 피라졸로피리딘 화합물
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
CN101862317A (zh) 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US7786112B2 (en) 2003-04-07 2010-08-31 Agennix Usa Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1615930A2 (en) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MY157911A (en) 2003-07-14 2016-08-15 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
GB0326168D0 (en) * 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1709051A1 (en) 2003-12-23 2006-10-11 GPC Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
KR20130006523A (ko) * 2004-02-17 2013-01-16 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
MXPA06009296A (es) * 2004-02-17 2007-01-26 Transoral Pharmaceuticals Inc Composiciones para suministro de agentes hipnoticos a traves de la mucosa oral y sus metodos de uso.
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
AR055054A1 (es) * 2005-04-22 2007-08-01 Wyeth Corp Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
KR20080031208A (ko) * 2005-05-25 2008-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 야반 불면증을 치료하기 위한 고체 조성물 및 방법
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20090234117A1 (en) * 2005-05-27 2009-09-17 Toshihiko Kashiwagi Pyrazolopyrimidine Derivative
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CA2611979A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles
EP1926734A1 (en) 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
EA200802118A1 (ru) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
DE102006029074A1 (de) 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
PL2081435T3 (pl) * 2006-09-22 2016-11-30 Inhibitory kinazy tyrozynowej brutona
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
WO2009065596A2 (en) * 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
MY159955A (en) 2008-01-04 2017-02-15 Intellikine Inc Certain chemical entities, compositions and methods
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
PL2266990T3 (pl) 2008-04-15 2013-03-29 Eisai R&D Man Co Ltd ZWIĄZEK 3-FENYLOPIRAZOLO[5,1-b] TIAZOLOWY
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
EP2331551B1 (en) 2008-08-26 2016-06-29 Evotec International GmbH Thienopyrimidines for pharmaceutical compositions
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP5819195B2 (ja) * 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
AR080326A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienipirimidinas que contienen cicloalquilo para composiciones farmaceuticas
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2562959T3 (es) 2010-02-26 2016-03-09 Evotec International Gmbh Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
BR112014003214A2 (pt) * 2011-08-11 2017-03-14 Intellikine Llc polimorfos inibidores de cinase
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
PL2766367T3 (pl) * 2011-10-14 2022-08-22 Scandion Oncology A/S Pochodne 4-amino-3-fenyloamino-6-fenylopirazolo[3,4-d]pirymidyny do leczenia infekcji wirusowych, zwłaszcza infekcji pikornawirusowych
DE102012004736A1 (de) 2011-10-20 2013-04-25 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidin-Derivate und deren Verwendung als antivirale Wirkstoffe
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
UA121104C2 (uk) 2013-10-04 2020-04-10 Інфініті Фармасьютикалз, Інк. Гетероциклічні сполуки і їх застосування
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US11034689B2 (en) * 2016-10-26 2021-06-15 The Trustees Of Indiana University Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment
US10729693B2 (en) * 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
CN110734439A (zh) * 2019-11-07 2020-01-31 中国药科大学 一种母核为吡唑并[3,4-d]嘧啶类化合物及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
US3551428A (en) * 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
FR1311787A (fr) * 1961-05-10 1962-12-14 Ciba Geigy Procédé de préparation de 4-mercapto-pyrazolo [3, 4-d] pyrimidines
FR2073274A1 (en) * 1969-12-15 1971-10-01 Sapchim Fournier Cimag Sa 4-mercapto-pyrazolo(3,4-d)-pyrimidines prepn
DE2430454A1 (de) * 1974-06-25 1976-01-15 Thomae Gmbh Dr K Neue pyrazolo eckige klammer auf 3,4d eckige klammer zu pyrimidine
US4139705A (en) * 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
JPS58208283A (ja) 1982-05-28 1983-12-03 Shigeji Ueda フルフリ−ルアルコ−ルを原料とし時日の変化を伴つても全然変色のない溶剤の製造法
US4426384A (en) 1982-08-05 1984-01-17 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5153352A (en) 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5391739A (en) * 1989-03-29 1995-02-21 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors

Also Published As

Publication number Publication date
IL107944A0 (en) 1994-04-12
PL177028B1 (pl) 1999-09-30
FI105920B (fi) 2000-10-31
NO305437B1 (no) 1999-05-31
CN1034175C (zh) 1997-03-05
EP0674642B1 (en) 2000-08-23
RU2124016C1 (ru) 1998-12-27
CN1094048A (zh) 1994-10-26
IL107944A (en) 2000-12-06
HU9303613D0 (en) 1994-04-28
DE69329296D1 (de) 2000-09-28
BR9307648A (pt) 1999-05-25
NO952399L (no) 1995-08-16
GR3034507T3 (en) 2000-12-29
ATE195738T1 (de) 2000-09-15
PL309359A1 (en) 1995-10-02
US6218397B1 (en) 2001-04-17
EP0674642A1 (en) 1995-10-04
DE69329296T2 (de) 2000-12-28
WO1994013677A1 (en) 1994-06-23
CZ158695A3 (en) 1995-11-15
FI935675A0 (fi) 1993-12-16
TW444018B (en) 2001-07-01
AU680226B2 (en) 1997-07-24
TW370529B (en) 1999-09-21
AU5728194A (en) 1994-07-04
HU221507B (en) 2002-10-28
ZA939405B (en) 1995-06-15
JPH07509728A (ja) 1995-10-26
KR0167395B1 (ko) 1999-01-15
KR100225720B1 (ko) 1999-10-15
FI935675A (fi) 1994-06-18
KR950704319A (ko) 1995-11-17
MY115300A (en) 2003-05-31
JP2862375B2 (ja) 1999-03-03
EG20273A (en) 1998-05-31
CA2150709A1 (en) 1994-06-23
HUT70426A (en) 1995-10-30
CZ287319B6 (en) 2000-10-11
DK0674642T3 (da) 2000-09-18
NZ259114A (en) 1997-03-24
NO952399D0 (no) 1995-06-16
PT674642E (pt) 2001-01-31
CA2150709C (en) 1999-03-16

Similar Documents

Publication Publication Date Title
ES2150482T3 (es) Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.
FI905983A0 (fi) Aminosyraderivat.
FI950309A (fi) Proliiniamidijohdannaisia
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
ATE61050T1 (de) Pyridazinamine wirksam gegen viren.
FI940807A (fi) Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta
ES2032381T3 (es) Un compuesto quimico. (reserva del art. 167.2 cpe).
ATE206708T1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
ATE79538T1 (de) Dispergierbare zubereitung.
FI924744A (fi) Terapeutiska aemnen
MX9800483A (es) Derivados de piperazina y su uso como antagonistas de 5-ht1a.
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
EP0302967A3 (en) Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
DK521685A (da) Spergualin-derivater og anvendelse deraf til fremstilling af laegemidler med immunosuppressiv virkning
SE8802814D0 (sv) Beredningar for lokal anvendning
YU119491A (sh) Novi protivirusni tetrahidroimidazo [1,4] benzodiazepin-2-(ti)oni i postupak njihovog dobijanja
GB942962A (en) New triazine and process for its manufacture
ES2153854T3 (es) Uso de compuestos de triazina para el tratamiento de trastornos de la memoria y del aprendizaje.
ES2116528T3 (es) Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.
MX9405318A (es) Pirimidonas e imidazolinonas para tratamiento del choque.
MX9205204A (es) Composicion farmaceutica que comprende compuestos antagonistas del receptor 5-hidroxitriptamina
ITMI931974A1 (it) Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674642

Country of ref document: ES